MCID: ISC004
MIFTS: 60

Ischemia

Categories: Blood diseases, Cardiovascular diseases, Metabolic diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Ischemia

MalaCards integrated aliases for Ischemia:

Name: Ischemia 11 53 43 14 16 71 75
Acute Coronary Syndrome 71

Classifications:



External Ids:

Disease Ontology 11 DOID:326
MeSH 43 D007511
NCIt 49 C34738
SNOMED-CT 68 52674009
UMLS 71 C0022116 C0948089

Summaries for Ischemia

Disease Ontology: 11 A vascular disease that is characterized by a restriction in blood supply to tissues.

MalaCards based summary: Ischemia, also known as acute coronary syndrome, is related to limb ischemia and lipoprotein quantitative trait locus, and has symptoms including muscle weakness, polydipsia and angina pectoris. An important gene associated with Ischemia is LINC01254 (Long Intergenic Non-Protein Coding RNA 1254), and among its related pathways/superpathways are Innate Immune System and Signal Transduction. The drugs Tenecteplase and Metformin have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, heart and brain, and related phenotypes are homeostasis/metabolism and nervous system

Wikipedia: 75 Ischemia or ischaemia is a restriction in blood supply to any tissue, muscle group, or organ of the... more...

Related Diseases for Ischemia

Diseases related to Ischemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2033)
# Related Disease Score Top Affiliating Genes
1 limb ischemia 33.3 VEGFA NOS3 HIF1A CXCL12 ACE
2 lipoprotein quantitative trait locus 33.2 VEGFA TLR2 PON1 NOS3 HIF1A CASP3
3 retinal ischemia 33.1 VEGFA HMOX1 HIF1A EPO CASP3
4 cerebral artery occlusion 32.8 VEGFA HMOX1 HIF1A CASP3
5 vascular disease 32.7 VEGFA SOD1 PON1 NOS3 HMOX1 CASP3
6 myocardial infarction 32.5 VEGFA TLR2 SOD2 SOD1 PON1 NOS3
7 microvascular complications of diabetes 5 32.3 VEGFA SOD2 SOD1 PON1 NOS3 HIF1A
8 myocardial stunning 32.2 SOD1 NOS3 ADORA3 ADORA1 ACE
9 carotid artery occlusion 32.2 VEGFA EPO CASP3
10 peripheral vascular disease 32.2 VEGFA NOS3 EPO ACE
11 aortic dissection 32.2 NOS3 HIF1A ACE
12 stroke, ischemic 32.2 VEGFA SOD2 PON1 NOS3 CXCL12 CDK5
13 brain edema 32.2 VEGFA SOD1 HMOX1 HIF1A
14 exudative vitreoretinopathy 1 32.1 VEGFA NOS3 HIF1A EPO CASP3
15 microvascular complications of diabetes 1 32.1 VEGFA HIF1A CXCL12
16 nephrosclerosis 32.1 VEGFA HIF1A CASP3 ACE
17 aortic aneurysm, familial thoracic 1 32.0 VEGFA NOS3 HIF1A ACE
18 intracranial berry aneurysm 32.0 VEGFA NOS3 HMOX1 EPO CASP3
19 coronary stenosis 31.9 PON1 CXCL12 ACE
20 peripheral artery disease 31.9 VEGFA NOS3 ACE
21 cerebrovascular disease 31.9 PON1 CASP3 APP ACE
22 hyperglycemia 31.8 TLR2 SOD2 SOD1 PRKAA2 NOS3 HIF1A
23 asphyxia neonatorum 31.8 HIF1A EPO CASP3
24 acute myocardial infarction 31.8 VEGFA PON1 NOS3 ACE
25 end stage renal disease 31.7 VEGFA SOD2 PON1 EPO ACE
26 pulmonary edema 31.7 NOS3 HIF1A EPO ACE
27 arteriosclerosis 31.6 PON1 HMOX1 HIF1A CXCL12 ACE
28 chronic kidney disease 31.6 SOD1 PON1 NOS3 EPO ACE
29 kidney disease 31.6 VEGFA PON1 NOS3 HMOX1 HIF1A EPO
30 pre-eclampsia 31.6 VEGFA SOD1 PON1 NOS3 HMOX1 HIF1A
31 congestive heart failure 31.6 VEGFA EPO ADORA1 ACE
32 toxic encephalopathy 31.5 SOD1 HMOX1 CDK5 CASP3 APP
33 carotid stenosis 31.5 VEGFA NOS3 ACE
34 heart disease 31.5 VEGFA TLR2 SOD2 SOD1 PON1 NOS3
35 atherosclerosis susceptibility 31.5 PON1 NOS3 HMOX1 ACE
36 cerebral palsy 31.4 SOD1 PON1 NOS3 HIF1A EPO
37 retinal vascular disease 31.4 VEGFA NOS3 HIF1A CASP3 ACE
38 vascular dementia 31.4 VEGFA PON1 APP ACE
39 pheochromocytoma 31.3 VEGFA SOD2 SOD1 HIF1A EPO EGR1
40 migraine with or without aura 1 31.3 VEGFA NOS3 ADORA3 ADORA1 ACE
41 type 2 diabetes mellitus 31.3 VEGFA TLR2 SOD2 SOD1 PRKAA2 PON1
42 macular retinal edema 31.2 VEGFA CXCL12 ACE
43 retinal artery occlusion 31.2 VEGFA HMOX1 ACE
44 hypertension, essential 31.2 VEGFA TLR2 SOD2 SOD1 PON1 NOS3
45 retinal vein occlusion 31.2 VEGFA CXCL12 ACE
46 diabetes mellitus 31.2 VEGFA TLR2 SOD2 SOD1 PRKAA2 PON1
47 pulmonary hypertension 31.2 VEGFA NOS3 HMOX1 HIF1A ACE
48 deficiency anemia 31.2 VEGFA SOD2 PON1 HMOX1 HIF1A EPO
49 eclampsia 31.1 VEGFA NOS3 ACE
50 sleep apnea 31.1 VEGFA NOS3 HIF1A EPO ACE

Graphical network of the top 20 diseases related to Ischemia:



Diseases related to Ischemia

Symptoms & Phenotypes for Ischemia

UMLS symptoms related to Ischemia:


muscle weakness; polydipsia; angina pectoris; anoxemia

MGI Mouse Phenotypes related to Ischemia:

45 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.45 ACE ADORA1 ADORA3 APP CASP3 CDK5
2 nervous system MP:0003631 10.42 ADORA1 APP CASP3 CDK5 CXCL12 EGR1
3 cardiovascular system MP:0005385 10.39 ACE ADORA1 ADORA3 APP CASP3 CXCL12
4 cellular MP:0005384 10.35 ACE APP CASP3 CXCL12 EGR1 EPO
5 muscle MP:0005369 10.34 APP CASP3 CXCL12 EPO HIF1A HMOX1
6 behavior/neurological MP:0005386 10.34 ACE ADORA1 ADORA3 APP CASP3 CDK5
7 growth/size/body region MP:0005378 10.32 ACE ADORA1 APP CASP3 EGR1 HIF1A
8 renal/urinary system MP:0005367 10.31 ACE ADORA1 ADORA3 CASP3 HIF1A HMOX1
9 liver/biliary system MP:0005370 10.29 ACE CXCL12 EGR1 EPO HIF1A HMOX1
10 immune system MP:0005387 10.28 ACE ADORA3 APP CASP3 CXCL12 EGR1
11 endocrine/exocrine gland MP:0005379 10.19 ACE CASP3 EGR1 HIF1A HMOX1 NOS3
12 neoplasm MP:0002006 10.13 ACE EGR1 HIF1A SOD1 SOD2 TLR2
13 respiratory system MP:0005388 10.11 ADORA1 ADORA3 CASP3 CDK5 EGR1 EPO
14 adipose tissue MP:0005375 10.08 ACE HIF1A HMOX1 NOS3 PRKAA2 SOD2
15 hematopoietic system MP:0005397 10.06 ACE ADORA1 ADORA3 APP CASP3 CXCL12
16 reproductive system MP:0005389 10.02 ACE APP CASP3 CXCL12 EGR1 HMOX1
17 vision/eye MP:0005391 9.96 ADORA3 APP CASP3 EGR1 HIF1A HMOX1
18 mortality/aging MP:0010768 9.83 ACE ADORA1 APP CASP3 CDK5 CXCL12
19 integument MP:0010771 9.36 ADORA1 ADORA3 APP CASP3 CDK5 EGR1

Drugs & Therapeutics for Ischemia

Drugs for Ischemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 837)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tenecteplase Approved Phase 4 191588-94-0
2
Metformin Approved Phase 4 1115-70-4, 657-24-9 4091
3
Lovastatin Approved, Investigational Phase 4 75330-75-5 53232
4
Etomidate Approved Phase 4 33125-97-2 667484
5
Nadroparin Approved, Investigational Phase 4
6
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
7
Promethazine Approved, Investigational Phase 4 60-87-7 4927
8
Hydromorphone Approved, Illicit Phase 4 466-99-9, 71-68-1 5284570
9
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
10
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
11
Vecuronium Approved, Investigational Phase 4 50700-72-6, 86029-43-8 39765 39764
12
Fenofibrate Approved Phase 4 49562-28-9 3339
13
Nicardipine Approved, Investigational Phase 4 55985-32-5 4474
14
Insulin glargine Approved Phase 4 160337-95-1 118984454
15
Racivir Approved, Investigational Phase 4 143491-57-0, 143491-54-7 60877
16
Fenoldopam Approved Phase 4 67227-56-9, 67227-57-0 3341
17
Zolpidem Approved Phase 4 82626-48-0 5732
18
Morphine Approved, Investigational Phase 4 57-27-2 5288826
19
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
20
Ibuprofen Approved Phase 4 15687-27-1 3672
21
Alprostadil Approved, Investigational Phase 4 745-65-3 5280723
22
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
23
Dobutamine Approved Phase 4 34368-04-2 36811
24
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
25
Amlodipine Approved Phase 4 88150-42-9 2162
26
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
27
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
28
Thrombin Approved, Investigational Phase 4
29
Milrinone Approved Phase 4 78415-72-2 4197
30
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
31
Oxytocin Approved, Vet_approved Phase 4 50-56-6 439302 53477758
32
Esmolol Approved, Withdrawn Phase 4 103598-03-4, 81147-92-4 59768
33
Quinapril Approved, Investigational Phase 4 82586-55-8, 85441-61-8 54892
34
Pravastatin Approved Phase 4 81093-37-0 54687
35
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
36
Polyestradiol phosphate Approved Phase 4 28014-46-2
37
Tocopherol Approved, Investigational Phase 4 1406-66-2
38
Simvastatin Approved Phase 4 79902-63-9 54454
39
Atenolol Approved Phase 4 29122-68-7 2249
40
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
41
Eplerenone Approved Phase 4 107724-20-9 443872
42
Abciximab Approved Phase 4 143653-53-6 3815015
43
Streptokinase Approved, Investigational Phase 4 9002-01-1
44
Argatroban Approved, Investigational Phase 4 74863-84-6 152951 92722
45
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
46
Atropine Approved, Vet_approved Phase 4 101-31-5, 5908-99-6, 51-55-8 3661 154417 174174
47
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
48
Cefuroxime Approved Phase 4 55268-75-2 5479529
49
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
50
Glyburide Approved Phase 4 10238-21-8 3488

Interventional clinical trials:

(show top 50) (show all 6100)
# Name Status NCT ID Phase Drugs
1 The Potential Effect of Omega3 Supplement in Fish Oil on Infarced Areas in the Brain and Improvement of Neurological Functions fo Ischemic Stroke Patients Unknown status NCT04386525 Phase 4
2 One Versus Twice Daily Administration of Multiple Cardiovascular Agents in Patients With Ischemic Heart Disease: An Open Label, Randomized, Multicenter Study Unknown status NCT04148820 Phase 4 Aspirin, Atorvastatin, Perindopril
3 Detection of Silent Atrial Fibrillation aFter Ischemic StrOke (SAFFO) Guided by Implantable Loop Recorder. Multicentre Italian Trial Based on Stroke Unit Network With Paired Cardio-Arrhythmology Units (Italian Neurocardiology Unit Network) Unknown status NCT02684825 Phase 4
4 Efficacy and Safety of New Generation Drug Eluting Stents Associated With an Ultra Short Duration of Dual Antiplatelet Therapy. Design of the Short Duration of Dual antiplatElet Therapy With SyNergy II Stent in Patients Older Than 75 Years Undergoing Percutaneous Coronary Revascularization. Unknown status NCT02099617 Phase 4
5 A Multicenter, Double Blind, Factorial Design, Phase IV Trial to Compare the Efficacy and Safety of Cilostazol Long-term Treatment With Aspirin in Ischemic Stroke Patients With High Risk of Cerebral Hemorrhage for the Prevention of Cerebral Hemorrhage and Cardiovascular Events and to Compare the Preventive Effect of Probucol in the Same Patient Group With Non-drug User Group for the Prevention of Cardiovascular Events Unknown status NCT01013532 Phase 4 Cilostazol;Probucol;Aspirin;placebo of cilostazol;placebo of aspirin
6 Double Blind Placebo Controlled Multicenter Trial for Prevention of IMT Progression in the Ischemic Stroke Patients With High Risk of Cerebral Hemorrhage With Cilostazol and Probucol Unknown status NCT02483169 Phase 4 cilostazol;Probucol;Aspirin;placebo of cilostazol;Placebo of aspirin
7 Ischemia In Hemodialysed Patients And Outcome: Ivabradine Versus Carvedilol. A Randomized, Double Blind Study Unknown status NCT01425164 Phase 4 Ivabradine;Carvedilol
8 Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI) Unknown status NCT01777503 Phase 4 prasugrel;Clopidogrel
9 Comparison of Hyperemic Efficacy Between Nicorandil and Adenosine for Fractional Flow Reserve (FFR) Measurement Unknown status NCT01331902 Phase 4
10 Effect of Evolocumab in Patients With Critical Limb Ischemia Unknown status NCT04306471 Phase 4 Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months.
11 Efficacy of Alprostadil as an Adjuvant Therapy With Indirect Angiosomal Revascularization in Patients With Critical Limb Ischemia. Unknown status NCT04312555 Phase 4 Alprostadil
12 Effects of Sevoflurane in Subanesthetic Concentrations on the Forearm Perfusion, Leukocyte/Thrombocyte Activation, and Endothelial Function After Tourniquet-Induced Ischemia/Reperfusion Injury in the Forearm of Volunteers Unknown status NCT00526695 Phase 4 Sevoflurane (Preconditioning)
13 Comparison of Cilostazol-based Triple Antiplatelet Therapy Versus Dual Antiplatelet Therapy for Outcomes of below-the Knee Endovascular Intervention in Patients With Critical Limb Ischemia (TAP CLI Study) Unknown status NCT02829151 Phase 4 Triple antiplatelet therapy (aspirin (100 mg), clopidogrel (75 mg), and cilostazol (200 mg) );Dual antiplatelet therapy (aspirin (100 mg) and clopidogrel (75 mg)) using aspirin and clopidogrel;Dual antiplatelet therapy (aspirin (100 mg) and cilostazol (200 mg)) using aspirin and cilostazol
14 The EPIC (Evaluating Perioperative Ischemia Reduction by Clonidine) Study: A Randomized, Double-blinded Trial of Clonidine for Reducing Cardiac Morbidity and Mortality Following Non-cardiac Surgery. Unknown status NCT00335582 Phase 4 clonidine hydrochloride
15 A Randomized, Single-blind, Controlled Clinical Trial of Cardiomyopeptidin Intervention in Patients With Acute ST-segment Elevation Myocardial Infarction Undergoing Direct PCI After Ischemia-reperfusion Injury Unknown status NCT03958422 Phase 4 cardiomyopeptidin
16 Optimized Strategy for Diabetic Patients With Critical Limb Ischemia: A Multi-center, Randomized Controlled Trial and Registration Study(Part I) Unknown status NCT01171703 Phase 4
17 DCLI-II:Optimized Strategy for Diabetic Patients With Critical Limb Ischemia: A Multi-center, Randomized Controlled Trial and Registration Study(Part II) Unknown status NCT01173094 Phase 4
18 A Randomized Study to Evaluate Safety and Efficacy of the ExcelTM Sirolimus Eluting Stent With a Biodegradable Polymer Versus SirOlimus ELUting Stent With Non-Biodegradable Polymer in the Treatment of PatIents With de nOvo Coronary Artery LesioNs Unknown status NCT00825773 Phase 4
19 A Comparative Evaluation of Efficacy and Safety in the 3-Months DAPT Group vs. the 6-Months DAPT Group of Patients Treated With the Coroflex ISAR Stent; A Prospective, Multicenter, Randomized, Open-Label Clinical Trial Unknown status NCT02609698 Phase 4 3 months DAPT;6 months DAPT
20 Increase in Capillary Plexus Density Level Following the Use of Ozurdex for the Treatment of DME (RMSM ICOD STUDY) Unknown status NCT04038125 Phase 4 Ozurdex Drug Implant Product
21 Bedside Testing of the CYP2C19 Gene to Asses Effectiveness of Clopidogrel in Coronary Artery Disease Patients Treated With Percutaneous Coronary Intervention : Individualized Antiplatelet Drugs Treatment to Improve Prognosis Unknown status NCT01823185 Phase 4 clopidogrel;Ticagrelor or prasugrel
22 Impact of Stent Platform on Shear Stress Distribution and Subsequent Vessel Healing After Drug-eluting Stent Implantation (SHEAR DES) Unknown status NCT01942044 Phase 4
23 Monitoring the Efficacy and Safety of Heparin and Nadroparin in the Acute Phase of Ischemic Stroke Unknown status NCT01862978 Phase 4 Heparin;Nadroparin;Placebo
24 Clinical Study of Argatroban in the Treatment of Acute Progressive Ischemic Stroke Unknown status NCT04275180 Phase 4 Argatroban
25 Low Dose Statins, Ezetimibe and Nutraceuticals in Coronary Artery Disease Patients Intolerant to High Intensity Statin Treatment (TArget ChOlesterol) Unknown status NCT03277079 Phase 4 statin + ezetimibe;statin + ezetimibe + Nutraceuticals
26 The Role of Qutenza (Topical Capsaicin 8%) in Treating Neuropathic Pain From Critical Ischaemia in Patients With End-stage Renal Failure Unknown status NCT01704339 Phase 4 QUTENZA
27 The Efficacy of Lescol XL(Fluvastatin Extended Release 80 mg) on Atherosclerosis Progression in Patients With Newly Diagnosed Coronary Heart Disease Unknown status NCT01681199 Phase 4 Fluvastatin extended release tablet
28 Randomized Trial of the Association Between Low-Dose Statins and Nutraceuticals in High-intEnsity Statin-intoleRant patiENts With Very High Risk Coronary Artery diseasE Unknown status NCT02001883 Phase 4 Association low-dose statin and nutraceuticals
29 Myocardial Revascularization in Patients With Ischemic Cardiomyopathy: a Comparison Between Percutaneous Coronary Intervention and Coronary Artery Bypass Surgery Unknown status NCT00388245 Phase 4
30 Ranolazine Effects on Ischemic Mitral Regurgitation Severity in Patients With Cardiac Resynchronization Therapy Unknown status NCT01979965 Phase 4 Ranolazine (Active drug);Placebo
31 Efficacy and Safety of Xueshuanxinmaining Tablet for the Treatment of Stable Angina Pectoris: Multicenter, Randomised, Double Blind, Placebo Controlled Trial Unknown status NCT04270279 Phase 4 Xueshuanxinmaining tablet;Xueshuanxinmaining placebo;Nitroglycerin tablets
32 Randomized Controlled Clinical Study to Compare the Efficacy and Safety of Different Dose of Tirofiban in Interventional Treatment of Complex Coronary Artery Disease Unknown status NCT02294994 Phase 4 tirofiban
33 The Diagnostic Benefits of HyperQTM vs. Conventional ECG During Stress Test. A Comparison Study in Women Referred to Angiography. Unknown status NCT00850486 Phase 4
34 Study of Curative Effect Evaluation of DanLou Tablet on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy Unknown status NCT03072082 Phase 4 Danlou Tablet;DanLou Tablet placebo;Aspirin Enteric-coated Tablets;Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet;Atorvastatin calcium;Isosorbide Mononitrate Tab 20 MG;Metoprolol Tartrate Tab 25 MG;Trimetazidine Dihydrochloride Tablets
35 The Efficacy and Safety of Paclitaxel-eluting SeQuent Please Drug-Eluting Balloon for Treatment of lesiOns in Native smalL coronarY Arteries (DEB-ONLY) Unknown status NCT01903902 Phase 4
36 A Randomized, Double-blind, Multi-centered, Placebo-controlled Trial to Examine Effects of Heart-protecting Musk Pill on Clinical Outcome in Patients With Chronic Stable Coronary Artery Disease Unknown status NCT01897805 Phase 4 Heart-protecting Musk Pill;Placebo
37 A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer Sirolimus-eluting Stent Safety and Effectiveness in Treatment of Coronary Artery Disease Unknown status NCT01880879 Phase 4
38 Cardiac Metabolic Modulator Treatment for Improvement of Left Ventricular Diastolic Function in Patients With Coronary Heart Disease: a Prospective, Randomized Controlled Study Unknown status NCT03887013 Phase 4 Trimetazidine
39 The Differentiation and Treatment Scheme of TCM Key Syndromes for the Treatment of Acute Disabling Ischemic Stroke: a Randomized, Double-Blind, Placebo-Controlled Multicenter Trial Unknown status NCT04199455 Phase 4 Integrative Treatment (EPACH Recipe Granules + NQABC Recipe Granules);Placebo
40 The Protective Effect of the α2-agonist Dexmedetomidine on Mitochondrial Structure and Function for Children With Non-cyanotic Congenital Heart Defects Having Cardiac Surgery: A Randomized Controlled Trial. Unknown status NCT02299063 Phase 4 Dexmedetomidine;0.9% NaCl
41 Xingnaojing for Moderate-to-severe Acute Ischemic Stroke (XMAS): A Multicenter, Prospective, Randomized, Open-label, Blinded Endpoint Clinical Trial. Unknown status NCT02728180 Phase 4 Xingnaojing injection
42 Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study (AFIRE Study) Unknown status NCT02642419 Phase 4 Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel);Rivaroxaban
43 The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial Unknown status NCT00724724 Phase 4 Butylphthalide Soft Capsules;Aspirin
44 A Multicenter, Open Labeled, Cross-Over Designed Prospective Study Evaluating the Effects of Lipid Lowering Treatment on Steroid Synthesis Unknown status NCT00433823 Phase 4 Atorvastatin, Ezetimibe
45 Cholesterol Reduction With Evolocumab and Coronary MicrovascuLar Function and Coronary Flow: The CHORAL Flow Study Unknown status NCT04073134 Phase 4 Placebo
46 Allopurinol in the Treatment of Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Treated by Either PCI or CABG: Pilot Study Unknown status NCT03700645 Phase 4 Allopurinol
47 The Efficacy of Glycemic Control With Continuous Glucose Monitoring on Atheroma Progression: Rationale and Design of the Observation of Coronary Atheroma Progression Under Continuous Glucose Monitoring Guidance in Patients With Type 2 Diabetes Mellitus Unknown status NCT04559191 Phase 4
48 Studies of Application of Combined General Anesthesia and Bilateral Thoracic Paravertebral Block by Ropivacaine in Patients Undergoing Off-pump Coronary Artery Bridge Graft - a Random Double Blind Controlled Study Unknown status NCT02727712 Phase 4 Anesthesia drugs during the surgery
49 Multicenter Trial on Clinical Utility of Acarbose in Patients With Ischemic Heart Disease Accompanied by Abnormal Glucose Regulation Unknown status NCT00858676 Phase 4 acarbose
50 Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy Unknown status NCT01869309 Phase 4 Prasugrel;Ticagrelor

Search NIH Clinical Center for Ischemia

Cochrane evidence based reviews: ischemia

Genetic Tests for Ischemia

Anatomical Context for Ischemia

Organs/tissues related to Ischemia:

MalaCards : Bone Marrow, Heart, Brain, Endothelial, Liver, Bone, Spinal Cord

Publications for Ischemia

Articles related to Ischemia:

(show top 50) (show all 31421)
# Title Authors PMID Year
1
Astrocyte targeted overexpression of Hsp72 or SOD2 reduces neuronal vulnerability to forebrain ischemia. 53 62
20235222 2010
2
Ischemia induces endoplasmic reticulum stress and cell apoptosis in human brain. 53 62
20347937 2010
3
Early and prominent alterations in hemodynamics, signaling, and gene expression following renal ischemia in sickle cell disease. 53 62
20107113 2010
4
Low-dose cardiotonic steroids increase sodium-potassium ATPase activity that protects hippocampal slice cultures from experimental ischemia. 53 62
19822191 2010
5
Vascular responses to hypoxia and ischemia. 53 62
19729615 2010
6
Effects of AMP-activated protein kinase in cerebral ischemia. 53 62
20010958 2010
7
Protective effect of albumin on VEGF and brain edema in acute ischemia in rats. 53 62
20138968 2010
8
The possible mechanism for impaired angiogenesis after transient focal ischemia in type 2 diabetic GK rats: different expressions of angiostatin and vascular endothelial growth factor. 53 62
19932587 2010
9
B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial. 53 62
20298924 2010
10
Angiogenic effects of stromal cell-derived factor-1 (SDF-1/CXCL12) variants in vitro and the in vivo expressions of CXCL12 variants and CXCR4 in human critical leg ischemia. 53 62
20206813 2010
11
Loss of clusterin expression worsens renal ischemia-reperfusion injury. 53 62
20007348 2010
12
Heme oxygenase-1 protects donor livers from ischemia/reperfusion injury: the role of Kupffer cells. 53 62
20222175 2010
13
Selective intrarenal human A1 adenosine receptor overexpression reduces acute liver and kidney injury after hepatic ischemia reperfusion in mice. 53 62
20065944 2010
14
A highlight of myoglobin diversity: the nitrite reductase activity during myocardial ischemia-reperfusion. 53 62
19836457 2010
15
Apurinic/apyrimidinic endonuclease APE1 is required for PACAP-induced neuroprotection against global cerebral ischemia. 53 62
20133634 2010
16
Cardiac protection by basic fibroblast growth factor from ischemia/reperfusion-induced injury in diabetic rats. 53 62
20190407 2010
17
Cardiac macrophage migration inhibitory factor inhibits JNK pathway activation and injury during ischemia/reperfusion. 53 62
19920350 2009
18
Blockade of Hsp20 phosphorylation exacerbates cardiac ischemia/reperfusion injury by suppressed autophagy and increased cell death. 53 62
19850943 2009
19
Allopurinol, xanthine oxidase, and cardiac ischemia. 53 62
19794315 2009
20
Association of cystatin C with ischemia in patients with coronary heart disease. 53 62
19816865 2009
21
Neuroprotection of ebselen against ischemia/reperfusion injury involves GABA shunt enzymes. 53 62
19576596 2009
22
Common micro-RNA signature in skeletal muscle damage and regeneration induced by Duchenne muscular dystrophy and acute ischemia. 53 62
19528256 2009
23
Retinal ischemia-induced apoptosis is associated with alteration in Bax and Bcl-x(L) expression rather than modifications in Bak and Bcl-2. 53 62
19862336 2009
24
Involvement of glutamate in retinal protection against ischemia/reperfusion damage induced by post-conditioning. 53 62
19682205 2009
25
Ischemia activates the ATF6 branch of the endoplasmic reticulum stress response. 53 62
19622751 2009
26
Impaired recovery of blood flow after hind-limb ischemia in mice lacking guanylyl cyclase-A, a receptor for atrial and brain natriuretic peptides. 53 62
19628785 2009
27
Enterocyte shedding and epithelial lining repair following ischemia of the human small intestine attenuate inflammation. 53 62
19753114 2009
28
Hypothermia attenuates ischemia/reperfusion-induced endothelial cell apoptosis via alterations in apoptotic pathways and JNK signaling. 53 62
19596001 2009
29
Both endogenous and exogenous testosterone decrease myocardial STAT3 activation and SOCS3 expression after acute ischemia and reperfusion. 53 62
19628067 2009
30
Pravastatin accelerates ischemia-induced angiogenesis through AMP-activated protein kinase. 53 62
19498441 2009
31
The E-selectin ligand basigin/CD147 is responsible for neutrophil recruitment in renal ischemia/reperfusion. 53 62
19443639 2009
32
Cardioprotection induced by adenosine A1 receptor agonists in a cardiac cell ischemia model involves cooperative activation of adenosine A2A and A2B receptors by endogenous adenosine. 53 62
19333129 2009
33
The neuronal apoptotic death in global cerebral ischemia in gerbil: important role for sodium channel modulator. 53 62
19115407 2009
34
Effects of overexpression of antioxidants on the release of cytochrome c and apoptosis-inducing factor in the model of ischemia. 53 62
19429031 2009
35
Angiopoietin-1 in the treatment of ischemia and sepsis. 53 62
18791498 2009
36
Effects of PACAP and preconditioning against ischemia/reperfusion-induced cardiomyocyte apoptosis in vitro. 53 62
19456402 2009
37
Circulating biochemical markers of brain damage in infants complicated by ischemia reperfusion injury. 53 62
19355873 2009
38
Ischemia detected on continuous electrocardiography after acute coronary syndrome: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction 36) trial. 53 62
19371824 2009
39
Therapeutic benefits of angiogenetic gene-modified human mesenchymal stem cells after cerebral ischemia. 53 62
19094989 2009
40
Neutrophil elastase inhibitor attenuates hippocampal neuronal damage after transient forebrain ischemia in rats. 53 62
19168036 2009
41
Transient postprandial ischemia is associated with increased intestinal fatty acid binding protein in patients with chronic gastrointestinal ischemia. 53 62
19279473 2009
42
Specific inhibition of hypoxia inducible factor 1 exaggerates cell injury induced by in vitro ischemia through deteriorating cellular redox environment. 53 62
19183269 2009
43
Expression of tissue-type transglutaminase (tTG) and the effect of tTG inhibitor on the hippocampal CA1 region after transient ischemia in gerbils. 53 62
19368835 2009
44
Agent-based model of therapeutic adipose-derived stromal cell trafficking during ischemia predicts ability to roll on P-selectin. 53 62
19247427 2009
45
Targeting STAT1 by myricetin and delphinidin provides efficient protection of the heart from ischemia/reperfusion-induced injury. 53 62
19116149 2009
46
FAK regulates cardiomyocyte survival following ischemia/reperfusion. 53 62
19028502 2009
47
Hypertension produced by placental ischemia in pregnant rats is associated with increased soluble endoglin expression. 53 62
19075097 2009
48
Atrogin-1/MAFbx enhances simulated ischemia/reperfusion-induced apoptosis in cardiomyocytes through degradation of MAPK phosphatase-1 and sustained JNK activation. 53 62
19117950 2009
49
Central role of Sp1-regulated CD39 in hypoxia/ischemia protection. 53 62
18812468 2009
50
Regulation of cardiac afferent excitability in ischemia. 53 62
19655108 2009

Variations for Ischemia

Copy number variations for Ischemia from CNVD:

6
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 72977 12 89000000 92600000 Copy number GALNT4 Acute coronary syndrome

Expression for Ischemia

Search GEO for disease gene expression data for Ischemia.

Pathways for Ischemia

Pathways related to Ischemia according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.87 VEGFA TLR2 SOD2 SOD1 NOS3 HMOX1
2 13.15 VEGFA PRKAA2 NOS3 HIF1A EPO EGR1
3
Show member pathways
12.94 APP CASP3 EGR1 HIF1A HMOX1 SOD1
4
Show member pathways
12.76 EPO HIF1A NOS3 PRKAA2 TLR2 VEGFA
5
Show member pathways
12.67 NOS3 EPO EGR1 CXCL12 ADORA3
6 12.56 VEGFA NOS3 HIF1A EGR1 CXCL12 CDK5
7
Show member pathways
12.34 NOS3 EGR1 CDK5 CASP3
8 12 VEGFA HIF1A EGR1 CASP3
9 11.76 VEGFA CXCL12 CASP3
10 11.75 PRKAA2 NOS3 CASP3
11 11.72 NOS3 HMOX1 HIF1A
12 11.63 CASP3 CXCL12 VEGFA
13
Show member pathways
11.57 SOD2 CDK5 APP
14
Show member pathways
11.49 SOD1 CASP3 APP
15 11.47 CXCL12 CDK5 APP
16 11.44 VEGFA HIF1A CASP3
17 11.2 VEGFA HIF1A EPO
18 11.19 VEGFA NOS3 HIF1A EPO
19 11.13 SOD2 SOD1 HMOX1
20
Show member pathways
11.06 VEGFA HIF1A EGR1
21 10.9 VEGFA NOS3 HIF1A
22 10.83 VEGFA HMOX1 HIF1A EPO CXCL12
23 10.59 VEGFA NOS3
24 10.58 SOD2 SOD1
25
Show member pathways
10.52 VEGFA HIF1A

GO Terms for Ischemia

Cellular components related to Ischemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuronal cell body GO:0043025 9.4 SOD1 SLC8A2 PRKAA2 CDK5 CASP3 ADORA1

Biological processes related to Ischemia according to GeneCards Suite gene sharing:

(show all 42)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.44 VEGFA TLR2 NOS3 HIF1A EGR1 APP
2 negative regulation of gene expression GO:0010629 10.35 VEGFA PRKAA2 HIF1A APP ACE
3 response to xenobiotic stimulus GO:0009410 10.3 SOD2 SOD1 HMOX1 CASP3 ACE
4 positive regulation of angiogenesis GO:0045766 10.29 VEGFA NOS3 HMOX1 HIF1A
5 aging GO:0007568 10.28 SOD2 SOD1 EPO ACE
6 negative regulation of cell population proliferation GO:0008285 10.25 TLR2 SOD2 NOS3 HMOX1 APP ADORA3
7 apoptotic process GO:0006915 10.2 TLR2 SOD1 HMOX1 HIF1A EPO CDK5
8 negative regulation of neuron apoptotic process GO:0043524 10.19 HIF1A HMOX1 SOD1 SOD2
9 response to heat GO:0009408 10.16 SOD1 NOS3 CXCL12
10 cognition GO:0050890 10.15 SLC8A2 APP ADORA1
11 visual learning GO:0008542 10.14 HIF1A CDK5 APP
12 positive regulation of blood vessel endothelial cell migration GO:0043536 10.11 VEGFA NOS3 HIF1A
13 neuron apoptotic process GO:0051402 10.11 HIF1A CDK5 CASP3 APP
14 response to oxidative stress GO:0006979 10.09 SOD2 SOD1 HMOX1 APP
15 response to axon injury GO:0048678 10.07 SOD2 SOD1 EPO
16 negative regulation of apoptotic process GO:0043066 10.06 VEGFA SOD2 SOD1 PRKAA2 HIF1A EPO
17 positive regulation of macroautophagy GO:0016239 10.03 HIF1A HMOX1 PRKAA2
18 response to nutrient levels GO:0031667 10.02 ACE PON1 SOD1 SOD2
19 positive regulation of neuron death GO:1901216 10 EGR1 CDK5 ADORA1
20 positive regulation of glycolytic process GO:0045821 10 PRKAA2 HIF1A APP
21 relaxation of vascular associated smooth muscle GO:0060087 9.99 SOD1 ADORA1
22 cellular oxygen homeostasis GO:0032364 9.97 HIF1A SOD2
23 positive regulation of axon extension involved in axon guidance GO:0048842 9.97 CXCL12 VEGFA
24 response to hydrogen peroxide GO:0042542 9.97 CASP3 HMOX1 SOD1 SOD2
25 modulation of excitatory postsynaptic potential GO:0098815 9.96 SLC8A2 APP
26 regulation of blood pressure GO:0008217 9.96 SOD2 SOD1 NOS3 HMOX1 ACE
27 regulation of transcription from RNA polymerase II promoter in response to oxidative stress GO:0043619 9.95 HMOX1 HIF1A
28 hemoglobin biosynthetic process GO:0042541 9.94 HIF1A EPO
29 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.93 VEGFA HIF1A
30 negative regulation of renal sodium excretion GO:0035814 9.93 ADORA1 ACE
31 response to superoxide GO:0000303 9.92 SOD2 SOD1
32 vasodilation GO:0042311 9.91 ADORA1 NOS3 SOD2
33 response to lipopolysaccharide GO:0032496 9.9 ACE CASP3 EPO NOS3 SOD2 TLR2
34 positive regulation of hormone biosynthetic process GO:0046886 9.88 HIF1A EGR1
35 microglia development GO:0014005 9.88 TLR2 APP
36 removal of superoxide radicals GO:0019430 9.88 SOD2 SOD1 NOS3
37 response to radiation GO:0009314 9.87 APP CXCL12 SOD2
38 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.85 VEGFA ACE
39 smooth muscle hyperplasia GO:0014806 9.84 NOS3 HMOX1
40 response to reactive oxygen species GO:0000302 9.8 SOD2 SOD1 HIF1A
41 positive regulation of chemokine production GO:0032722 9.65 TLR2 HMOX1 HIF1A EGR1 APP
42 response to hypoxia GO:0001666 9.64 VEGFA TLR2 SOD2 HMOX1 HIF1A EPO

Molecular functions related to Ischemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled adenosine receptor activity GO:0001609 9.26 ADORA3 ADORA1
2 superoxide dismutase activity GO:0004784 8.92 SOD2 SOD1

Sources for Ischemia

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....